Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

El.En.

Investor Presentation • Jan 25, 2017

4393_cp_2017-01-25_795c383a-a9de-4d7d-b933-e42321ee9a5f.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

COMPANYPRESENTATION

Frankfurt, 25.01.2017

DISCLAIMER

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward‐looking statements. Forward‐looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward‐looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward‐looking statements. The Company undertakes no obligation about the contents nor to update the forward‐looking statements to reflect events or circumstances that may arise after the date hereof.

SUMMARY

‐El.En. Group

HISTORY

GROUPOVERVIEW

Hi‐Tech company

Hi‐Tech industrial group active in opto‐electronics with proprietary technology and know how developed over 35 years

International Group

More than 30 companies active worldwide in complementary markets and application segments. Listed on the Milan Stock Exchange

Among the leaders in the global market

Progressively widening its worldwide presence registered continuous growth over the years

Worldwide distribution network

1060 employees worldwide, more than 40,000 laser sources sold

FY 2015

Consolidated Revenue at €218 mln, up 21% YoY

9M 2016

Consolidated Revenue at €180 mln, up 15% YoY

DIVISION

El.En. designs, manufactures ad sells worldwide: MEDICAL laser devices – INDUSTRIAL laser solutions – laser systems for CONSERVATION OF THE CULTURAL HERITAGE

EL.EN.WORLDWIDE

8

STRATEGICSTRENGTHS

MULTIDISCIPLINARY AND MULTIFACILITY R&D ACTIVITY: SOURCES – SYSTEMS ‐ APPLICATIONS

INDUSTRIAL

Combine High tech laser source development with flexible production facilities focusing on applications

MEDICAL

Technological and clinical innovation improving performances and broadening the application scope of our laser systems

  • New applications
  • Improved efficacy and effectiveness of current applications

Leverage worldwide distribution with multi brand approach

CONSOLIDATEDREVENUE AND EBIT

R&DACTIVITY

CLINICAL TRIALS AND VALIDATIONS OF NEW THERAPEUTIC LASER TREATMENTS AND RESEARCH ON NEW APPLICATIONS OF LASER‐TISSUE INTERACTION

  • Broadening Mona Lisa Touch Clinical studies
  • New Pico second laser platform
  • Clinical studies on cutaneous ulcers
  • Painless laser hair removal
  • Patents development
  • Increased power of RF laser sources
  • Innovative applications for mid power laser systems
  • High power metal cutting laser systems

2‐Laser: Applications and Markets

LASER

Light Amplification by Stimulated

Emission of Radiation

MEDICALAPPLICATIONS

SURGICALLASER SYSTEMS

AESTETICAPPLICATIONS

AESTHETICLASER SYSTEMS

MOTUS AX

THEMEDICAL LASER MARKET

Global market for medical lasers by end use, through 2019 (\$ millions)

k
S
M
t
t
a
r
e
e
m
e
n
g		 2
0
1
4		 2
0
1
9		 C
G
%
A
R
2
0
1
4
2
0
1
9
‐
l
S
i
r
a
u
g
c		 8
1
3		 1
2
1
9		 8
4
%
,
C
i
t
o
s
m
e
c		 1
0
2
4		 2
0
9
7		 1
5
4
%
,
l
D
t
e
n
a		 2
4
4		 6
2
3		 2
0
%
7
,
i
V
t
e
e
r
n
a
r
y		 1
1
5		 2
4
7		 1
6
%
5
,
l
T
t
o
a		 2
9
1
5		 8
4
1
5		 3
8
%
1
,

Source: BCC research

INDUSTRIALLASERS APPLICATIONS

AUTOMOTIVELABELINGDIGITAL CONVERTINGPACKAGINGEASY OPENING DECORATION

INDUSTRIAL CO2LASER SOURCES

RF177

RF888

INDUSTRIALLASER SYSTEMS

THEINDUSTRIAL LASER MARKET

Global market and forecast for high power laser systems, by application (by value)

l
B
V
y
a
u
e		 C
A
G
R		 (
)
%
2
0
1
6		 2
0
2
0		 2
0
1
3
2
0
1
6
‐		 2
0
1
6
2
0
2
0
‐
C
i
t
t
u
n
g		 3
0
1
4		 3
9
6
5		 7
8
,		 7
1
,
l
d
d
i
i
W
B
e
n
g
a
n
r
a
z
n
g		 1
6
0
5		 2
2
3
1		 8
7
,		 8
6
,
f
d
h
S
O
t
t
t
t
r
a
c
e
r
e
a
m
e
n
a
n
e
r
u		 6
3		 8
6		 8
3
,		 8
1
,
l
T
t
o
a		 6
8
2
4		 6
2
8
2		 8
1
,		 6
7
,

Source: Optech Consulting

3‐ 9 MONTHS 2016 FINANCIALRESULTS

CONSOLIDATEDP&L – 9 MONTHS

/
E
0
0
0
u
r
o		 /
/
3
0
0
9
1
5		 /
/
3
0
0
9
1
6		 %
V
a
r.
R
e
e
n
e
s
v
u		 6
0
0
6
1
5		 1
0
0
0
%
,		 9
6
1
7
5
5		 1
0
0
0
%
,		 1
1
%
5
,
i
G
r
o
s
s
m
a
r
g
n		 0
2
3
6
7		 0
%
4
5
,		 8
6
2
3
7		 3
8
%
4
,		 1
1
9
%
,
i
O
E
t
p
e
r
a
n
p
e
n
s
e
s
g
x		 2
0
8
9
7		 3
3
%
1
,		 2
2
8
7
5		 2
%
1
7
,		 0
0
%
1
,
f
f
S
t
a
e
s
p
e
n
s
e
s		 3
0
3
6
1		 9
3
%
1
,		 3
2
8
7
5		 8
3
%
1
,		 8
8
%
,
E
B
I
T
D
A		 9
3
0
1
1		 2
%
1
4
,		 2
2
9
6
2		 2
8
%
1
,		 8
9
%
1
,
l
D
t.
e
p
r.
a
m
o
r
a
r
a
s
c
c
u
,
,		 3
1
1
7		 2
0
%
,		 3
9
3
1		 8
%
1,		 2
%
4
,
E
B
I
T		 6
9
3
1
1		 0
%
1
4
,		 9
6
9
1
7		 0
%
1
1
,		 2
2
%
1
,
(
)
f
h
i
i
N
t
e
n
a
n
c
n
c
o
m
e
c
a
r
g
e
s		 8
8
1		 0
6
%
,		 (
)
6
7
5		 0
%
4
‐
,
(
)
h
i
O
t
t
e
r
n
c
o
m
e
e
x
p
e
n
s
e
n
e		 1
1
7		 %
0
1
,		 2
2
9
3
3		 %
1
2
8
,		 %
1
9
4
4
4
0
,
E
B
T		 1
7
1
9
1		 0
%
1
1
,		 4
2
0
2
7		 2
3
%
4
,		 %
1
4
4
5
,

NETFINANCIAL POSITION AND CAPEX

'0
0
E
u
r
o		 /
/
3
1
1
2
1
5
0
f
l
i
i
i
i
N
t
t
e
n
a
n
c
a
p
o
s
o
n
:		 2
9
8
1
5		 2
2
2
2
7
/
l
l
i
i
i
F
t
t
n
a
n
c
a
n
v
e
s
m
e
r
m
:		 1
0
6
4
3		 1
0
7
9
8
i
i
d
d
i
d
D
e
n
p
a
v
d
f
h
l
P
C
r
o
c
e
e
s
r
o
m
y
n
o
s
a
r
e
s
s
a
e		 6
3
8
4
3
9
8
8
0
'0
E
0
0
u
r
o		 /
/
3
0
0
9
1
5		 /
/
3
0
0
9
1
6		 /
Q
3
1
6
C
a
p
e
x		 9
3
4
4		 9
2
5
5		 0
2
5
4
l
d
l
d
l
i
i
&
B
t
u
n
g
s,
a
n
s
p
a
n
s		 3
1
0
0		 8
1
0
0		 4
6
0
0
h
O
t
e
r
s		 8
3
1
4		 2
1
4
5		 2
4
4

REVENUEBREAKDOWN BY BUSINESS

REVENUEBREAKDOWN BY AREA

MEDICALLASERS BUSINESS REVENUE

INDUSTRIALLASERS BUSINESS REVENUE

4‐2016 TARGETS

Sales 2016 = +10%-> €239 mln

EBIT 2016 = +15%-> €25 mln

5 EL.EN. STOCK, MULTIPLES &COMPARABLES

EL.EN.STOCK

EL.EN.MULTIPLES

's
k
h
l
d
i
h
S
E
t
t
o
c
o
e
r
q
p
e
r
s
a
r
e
u
y		 9
/
i
k
l
d
j.
P
B
V
A
r
c
e
o
o
a
u
e		 2,
6
/
(
)
V
I
8
%
I
E
E
B
T
5
E
B
T		 1
6,
4
/
l
(
l
)
S
8
%
S
E
V
5
a
e
s
a
e
s		 8
1,
l.
k
C
E
E
M
t
n
a
r
e
a
p		 4
0,
4
@
5		 €
2
3,
3
4
f
l
i
i
i
i
N
t
t
e
n
a
n
c
a
p
o
s
o
n		 2,
2
@
7		 /
/
3
0
0
9
6
1
/
l
l
i
i
i
F
t
t
t
n
a
n
c
a
n
e
s
m
e
n
s
m
e
r
m
v		 @
1
0,
8		 /
/
3
0
0
9
1
6
i
l
E
V
t
n
e
r
p
r
s
e
a
e
u		 3
6
7,
4

EL.EN.COMPARABLES

h,
Se
3
0t
2
0
1
6
t.
p
Pr
ice		 Re
ve
nu
e		 Va
%
r.		 E
B
I
T		 E
B
I
T
%		 M
K.
Ca
p.		 E
V		 /
les
E
V
Sa		 /
E
V
E
B
I
T		 /
(
*)
P
E		 /
k
P
Bo
o
/
d
ica
l
he
ic
Me
Ae
st
t		 Re
ve
nu
e		 (
*)		 (
*)		 lue
Va
Sy
ne
ro
n		 \$
8,
6
0		 \$
2
1
5.
2
1
0		 %
8		 \$
3.
0
0
2		 %
1		 \$
2
9
0.
0
8
0		 \$
2
0
7.
1
8
5		 0,
7		 5
1,
8		 2
0
1,
4		 1,
4
lt
iq
Ze		 \$
0,
8
9
4		 \$
2
9.
0
9
4
1		 %
4
1		 \$
(
)
3.
0
3
4		 %
1
‐		 \$
6
0.
0
0
0
1.
1		 \$
8.
2
1.
5
4
5
5		 4,
7		 n.
a.		 n.a 3,
2
1
Cu
te
ra		 \$
8,
1
7
5		 \$
8
0.
8
1
1		 2
%
4		 \$
(
)
2.
0
8
4		 3
%
‐		 \$
2
2
0
0
4
4.		 \$
9
8
1
7.
1
7		 9
1,		 n.
a.		 n.
a.		 4,
7
io
las
B
e		 \$
1,
5
5		 \$
3
8.
0
4
9		 1
2
%		 \$
(
)
1
0.
8
4
8		 2
9
%
‐		 \$
1
0
4
3
0
5.		 \$
9
2.
6
1
5		 1,
8		 n.
a.		 n.
a.		 4,
0
Cy
no
su
re		 \$
4
3,
7
5		 \$
3
1
1.
3
9
3		 3
1
%		 \$
2
3.
1
1
3		 7
%		 \$
1.
0
4
0.
0
0
0		 \$
8
4
3.
6
6
8		 2,
0		 2
7,
4		 5
8,
4		 2,
3
du
l
In
ia
str
ho
ics
I
P
G
P
Co
to
n		 \$
1
0
0,
8
3		 \$
7
2
6.
0
5
2		 7
%		 \$
2
5
9.
1
1
3		 3
6
%		 \$
5.
3
3
0.
0
0
0		 \$
4.
5
6
0.
6
6
0		 4,
7		 1
3,
2		 2
1,
5		 3,
5
im
du
ie
Pr
In
str
a		 \$
1
7,
1
4		 \$
2
7
4.
5
3
6		 6
%		 \$
1
2.
3
1
6		 4
%		 \$
1
7
9.
6
8
0		 \$
3
0
1.
9
3
2		 0,
8		 1
8,
4		 2
4,
0		 1,
4
l.
(
)
E
En
1		 \$
2
3,
3
4		 \$
1
7
9.
5
6
5		 1
5
%		 \$
1
9.
7
6
9		 1
1
%		 \$
4
5
0.
4
0
3		 \$
3
6
7.
3
8
3		 1,
8		 1
6,
4		 1
2,
0		 2,
6
(
2
9,
9		 **
)

(1) EV and multiplies as for previous slide

(*) Revenue,Ebit and earnings annualized

(**) w/o one time income

El.En. SPA

Enrico ROMAGNOLI Investor Relations Manager tel. +39 055‐8826807E‐mail: [email protected]

POLYTEMS HIR SRL

Bianca FERSINI MASTELLONIFinancial CommunicationTel. +39 06‐6797849 / +39 06‐69923324 E‐mail: [email protected]

POLYTEMS HIR SRL

Silvia MARONGIU Press office Tel. +39 06‐6797849 / +39 06‐69923324 E‐mail: [email protected]

More from El.En.

Regulatory Filings 2025
Dec 22
Transaction in Own Shares 2025
Dec 22
Share Issue/Capital Change 2025
Dec 22
Transaction in Own Shares 2025
Dec 3
Investor Presentation 2025
Dec 3
Report Publication Announcement 2025
Dec 3
Report Publication Announcement 2025
Dec 3
Registration Form 2025
Nov 28
Share Issue/Capital Change 2025
Nov 28
Share Issue/Capital Change 2025
Nov 28
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.